Tel:+86-027-59403931 Ext 8009 
Email: wwqin@oryzogen.com
Contact Us
Inquiry Now 
News
-
07
2025-08
OsrHSA Listed as MIIT Landmark Biomanufacturing Product
Recombinant Human Albumin(Oryza sativa) Selected into List of Landmark Biomanufacturing Products by the Ministry of Industry and Information Technology of the People's Republic of China
-
26
2025-06
Clinical Trial Data of Recombinant Human Albumin Injection (Oryza Sativa) was published in the journal “Gut”
"OsrHSA Recombinant Human AlbuminInjection provides a more accessible alternative for cirrhosis patients, especially in plasma-derived HSAresourcelimited regions," said the leading investigator of the study.
-
18
2025-07
First-in-Class: Recombinant Human Albumin Injection (Oryza Sativa) Approved by China NMPA
Healthgen’s “Recombinant Human Albumin Injection(Oryza Sativa)” was approved by the China’s National Medical Products Administration (NMPA)on 18 July, 2025.